Phase II trial of cancer vaccine MUC-1 [CVac] in patients with resectable triple-negative breast cancer.

Trial Profile

Phase II trial of cancer vaccine MUC-1 [CVac] in patients with resectable triple-negative breast cancer.

Planning
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Cancer vaccine MUC-1 (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Nov 2017 According to a Prima BioMed media release, Prima BioMed changed its name to Immutep Limited.
    • 25 Jun 2013 New trial record
    • 24 Jun 2013 The trial protocol will be finalised and applications for regulatory and ethics committee approvals will be initiated in the coming months, according to a Prima Biomed media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top